Literature DB >> 7848602

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.

T Wrin, J H Nunberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7848602     DOI： 10.1097/00002030-199411000-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  29 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

4.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Authors:  Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Antu K Dey; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

5.  Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  X Yang; M Farzan; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

7.  Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.

Authors:  K E Follis; M Trahey; R A LaCasse; J H Nunberg
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.

Authors:  J E Johnson; M J Schnell; L Buonocore; J K Rose
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

9.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

10.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.